Product cited in:
Ohta, Iwai, Kasahara et al.: "Immunoblot analysis of cellular expression of Bcl-2 family proteins, Bcl-2, Bax, Bcl-X and Mcl-1, in human peripheral blood and lymphoid tissues." in: International immunology, Vol. 7, Issue 11, pp. 1817-25, 1996 (PubMed).
Oltvai, Milliman, Korsmeyer: "Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death." in: Cell, Vol. 74, Issue 4, pp. 609-19, 1993 (PubMed).
Reed: "Bcl-2 and the regulation of programmed cell death." in: The Journal of cell biology, Vol. 124, Issue 1-2, pp. 1-6, 1994 (PubMed).
Yin, Oltvai, Korsmeyer: "BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax." in: Nature, Vol. 369, Issue 6478, pp. 321-3, 1994 (PubMed).
Krajewski, Krajewska, Shabaik et al.: "Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2." in: The American journal of pathology, Vol. 145, Issue 6, pp. 1323-36, 1995 (PubMed).
Krajewski, Blomqvist, Franssila et al.: "Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma." in: Cancer research, Vol. 55, Issue 19, pp. 4471-8, 1995 (PubMed).